Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic
Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic
05/13/24, 11:04 AM
Location
new yorkMoney raised
$95 million
Industry
biotechnology
Round Type
series c
Investors
Inning One Ventures, Schrödinger, Inc., Boxer Capital, Eco R1 Capital, Point72, Ra Capital Management, Vivo Capital, Eli Lilly And Company, Goldman Sachs Alternatives
Ajax Therapeutics, Inc. announced the closing of an oversubscribed $95 million Series C financing. The proceeds will be used to support the clinical development of Ajax’s first-in-class Type II JAK2 inhibitor, AJ1‑11095, for the treatment of myelofibrosis, as well as advancing the company’s pipeline of treatments for MPNs.
Company Info
Location
275 madison ave, 39th floor
new york, new york, united states
Additional Info
Ajax Therapeutics, Inc. is pursuing uniquely selective approaches to develop novel next generation therapies for myeloproliferative neoplasms (MPNs), including myelofibrosis. By combining the deep cancer and structural biology insights of our founding scientists with the industry’s most advanced computational drug discovery and protein structure platforms, we aim to discover and develop more precisely designed therapies to address the significant unmet needs for patients with MPNs.